A5015975033- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Melanoma and MAPK Pathways
- Immunotherapy and Immune Responses
- Cutaneous Melanoma Detection and Management
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Peptidase Inhibition and Analysis
- Breast Cancer Treatment Studies
- Lung Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Neutropenia and Cancer Infections
- Cancer therapeutics and mechanisms
- Monoclonal and Polyclonal Antibodies Research
- Chemotherapy-induced cardiotoxicity and mitigation
- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
- Brain Metastases and Treatment
- Cancer Genomics and Diagnostics
- Polyomavirus and related diseases
- Chemotherapy-related skin toxicity
- Synthesis and Biological Evaluation
- Nonmelanoma Skin Cancer Studies
- Nutrition and Health in Aging
University of Alberta
2009-2023
Cancer Institute (WIA)
2005-2021
Alberta Cancer Foundation
1996-2021
College of the Holy Cross
2018
Regional Cancer Center
2017
Dana-Farber Cancer Institute
2017
University of Pittsburgh Medical Center
2017
Greater Baltimore Medical Center
2017
National Health Service
2017
Memorial Sloan Kettering Cancer Center
2017
Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab cytotoxic T-lymphocyte–associated antigen 4 [CTLA-4] have been shown to complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or plus was compared with patients
We conducted a randomized, placebo-controlled, double-blind trial to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non–small-cell lung cancer after failure of first-line or second-line chemotherapy.
Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than alone phase 3 trial involving patients advanced melanoma. We now report 3-year overall outcomes this trial.
Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than a trial involving patients with advanced melanoma. We now report 5-year outcomes the trial.
Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In United States, has also as adjuvant therapy melanoma on basis recurrence-free overall survival rates were higher than those with placebo in a phase 3 trial. We wanted to determine efficacy nivolumab versus patients resected this randomized, double-blind, trial, we randomly assigned 906 (≥15 years age) who undergoing complete resection stage IIIB, IIIC, or IV receive an...
On the basis of data from a phase 2 trial that compared checkpoint inhibitor ipilimumab at doses 0.3 mg, 3 and 10 mg per kilogram body weight in patients with advanced melanoma, this evaluated dose who had undergone complete resection stage III melanoma.After cutaneous we randomly assigned them to receive (475 patients) or placebo (476) every weeks for four doses, then months up years until disease recurrence an unacceptable level toxic effects occurred. Recurrence-free survival was primary...
In phase I/II trials, the cytotoxic T lymphocyte-associated antigen-4-blocking monoclonal antibody tremelimumab induced durable responses in a subset of patients with advanced melanoma. This III study evaluated overall survival (OS) and other safety efficacy end points melanoma treated or standard-of-care chemotherapy.Patients treatment-naive, unresectable stage IIIc IV were randomly assigned at ratio one to (15 mg/kg once every 90 days) physician's choice chemotherapy (temozolomide...
Purpose Until recently, limited options existed for patients with advanced melanoma who experienced disease progression while receiving treatment ipilimumab. Here, we report the coprimary overall survival (OS) end point of CheckMate 037, which has previously shown that nivolumab resulted in more achieving an objective response compared chemotherapy regimens ipilimumab-refractory melanoma. Patients and Methods were stratified by programmed death-ligand 1 expression, BRAF status, best prior...
In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and alone versus ipilimumab. Here, we report 6.5-year efficacy safety outcomes.Patients untreated unresectable stage or IV melanoma were randomly assigned 1:1:1 to receive 1 mg/kg 3 once every weeks (four doses) followed by 2 (n = 314), 316), doses; n 315). Coprimary end points progression-free survival overall (OS) Secondary included objective response rate, descriptive...
PURPOSE Nivolumab 1 mg/kg plus ipilimumab 3 (NIVO1+IPI3) is approved for first-line treatment of patients with advanced melanoma in several countries. We conducted a phase IIIb/IV study (CheckMate 511) to determine if nivolumab (NIVO3+IPI1) improves the safety profile combination. PATIENTS AND METHODS Patients (N = 360) age 18 years or older previously untreated, unresectable stage III IV were randomly assigned 1:1 NIVO3+IPI1 NIVO1+IPI3 once every weeks four doses. After 6 weeks, all...
9506 Background: In the phase 3 CheckMate 067 trial, a durable and sustained clinical benefit was achieved with nivolumab (NIVO) + ipilimumab (IPI) NIVO alone vs IPI at 5-y of follow-up (overall survival [OS] progression-free [PFS] rates: 52%, 44%, 26% 36%, 29%, 8%, respectively). Here we report 6.5-y efficacy safety outcomes. Methods: Eligible pts previously untreated unresectable stage III or IV melanoma were randomly assigned in 1:1:1 ratio stratified by PD-L1 status, BRAF mutation...
9522 Background: Durable clinical benefit has been achieved with nivolumab (NIVO) + ipilimumab (IPI), including an overall survival (OS) of 49% and a melanoma-specific (MSS) 56%, median MSS not reached (NR) at 6.5-y minimum follow-up. Here we report sustained efficacy outcomes 7.5 y. Methods: Patients (pts) previously untreated, unresectable stage III/IV melanoma were randomly assigned 1:1:1 stratified by PD-L1 status, BRAF mutation metastasis to receive NIVO 1 mg/kg IPI 3 for 4 doses Q3W,...
Background: Preclinical data indicate that docetaxel, platinum salts, and the combination of both drugs are highly synergistic with anti-HER2 antibody trastuzumab. The University California at Los Angeles-Oncology Research Network (UCLA-ORN) Breast Cancer International Group (BCIRG) have conducted two phase II studies to evaluate docetaxel trastuzumab in either cisplatin or carboplatin for treatment women advanced breast cancer overexpresses HER2. Methods: Each study enrolled 62 patients...
Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC). This trial was undertaken to determine whether adjuvant treatment the metalloproteinase inhibitor marimastat could prolong survival responding patients SCLC after chemotherapy.SCLC complete or partial remission were eligible. They stratified by radiotherapy (early, late, none), stage (extensive limited), response (complete partial), and cooperative group (National Cancer Institute...
This double-blind randomized phase II trial examined whether vandetanib, an inhibitor of vascular endothelial and epidermal growth factor receptors, could prolong progression-free survival in responding patients with small-cell lung cancer.Eligible complete response (CR) or partial (PR) to combination chemotherapy (+/- thoracic prophylactic cranial radiation) received oral vandetanib 300 mg/d matched placebo. With 100 77 events, the study had 80% power detect improvement median from 4 6.5...
Purpose We report a multicenter phase II study of patients with metastatic melanoma (MM), evaluating the efficacy, toxicity, progression-free survival (PFS), immunogenicity, and biomarker profile interleukin-21 (IL-21). Patients Methods no prior systemic therapy limited-disease MM were treated IL-21 by using three different dosing regimens. Cohort 1 received 50 μg/kg per day outpatient intravenous bolus injection for 5 days each week during weeks 1, 3, an 8-week cycle. 2 30 on same schedule,...
Abstract Blockade of the programmed cell death 1 (PD-1)/programmed death-ligand (PD-L1) interaction has emerged as a powerful strategy in cancer immunotherapy. Recently, there have been enormous efforts to develop potent PD-1/PD-L1 inhibitors. In particular, Bristol-Myers Squibb (BMS) and Aurigene Discovery Technologies individually disclosed several promising inhibitors, whose detailed experimental data are not publicly disclosed. this work, we report rigorous systematic vitro...